Long‐Term Corticosteroid‐Sparing Immunosuppression for Cardiac Sarcoidosis. Issue 18 (17th September 2019)

• Record Type: Journal Article
• Authors: Rosenthal, David G.; Parwani, Purvi; Murray, Tyler O.; Petek, Bradley J.; Benn, Bryan S.; De Marco, Teresa; Gerstenfeld, Edward P.; Janmohamed, Munir; Klein, Liviu; Lee, Byron K.; Moss, Joshua D.; Scheinman, Melvin M.; Hsia, Henry H.; Selby, Van; Koth, Laura L.; Pampaloni, Miguel H.; Zikherman, Julie; Vedantham, Vasanth
• Is Part Of: Journal of the American Heart Association. Volume 8:Issue 18(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-09-17
• Subjects: immunosuppression -- sarcoidosis -- ventricular arrhythmia; Heart -- Diseases -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cerebrovascular disease -- Periodicals; Cardiology -- Periodicals; 616.1
• DOI: 10.1161/JAHA.118.010952
• Languages: English
• ISSNs: 2047-9980

Abstract

Abstract : Background: Long‐term corticosteroid therapy is the standard of care for treatment of cardiac sarcoidosis (CS). The efficacy of long‐term corticosteroid‐sparing immunosuppression in CS is unknown. The goal of this study was to assess the efficacy of methotrexate with or without adalimumab for long‐term disease suppression in CS, and to assess recurrence and adverse event rates after immunosuppression discontinuation. Methods and Results: Retrospective chart review identified treatment‐naive CS patients at a single academic medical center who received corticosteroid‐sparing maintenance therapy. Demographics, cardiac uptake of 18‐fluorodeoxyglucose, and adverse cardiac events were compared before and during treatment and between those with persistent or interrupted immunosuppression. Twenty‐eight CS patients were followed for a mean 4.1 (SD 1.5) years. Twenty‐five patients received 4 to 8 weeks of high‐dose prednisone (>30 mg/day), followed by taper and maintenance therapy with methotrexate±low‐dose prednisone (low‐dose prednisone, <10 mg/day). Adalimumab was added in 19 patients with persistently active CS or in those with intolerance to methotrexate. Methotrexate±low‐dose prednisone resulted in initial reduction (88%) or elimination (60%) of 18‐fluorodeoxyglucose uptake, and patients receiving adalimumab‐containing regimens experienced improved (84%) or resolved (63%) 18‐fluorodeoxyglucose uptake. Radiologic relapse occurred in 8 of 9 patients after immunosuppression cessation, 4 patients on methotrexate‐containing regimens, and in no patients on adalimumab‐containing regimens. Conclusions: Corticosteroid‐sparing regimens containing methotrexate with or without adalimumab is an effective maintenance therapy in patients after an initial response is confirmed. Disease recurrence in patients on and off immunosuppression support need for ongoing radiologic surveillance regardless of immunosuppression regimen.